|
|
|
|
 Jean-Jacques Garaud,
Head of Pharma Research and Early Development Roche Position
Head Roche Pharma Research & Early Development (pRED) and member of the Enlarged Roche Corporate Executive Committee
Studies
• University of Paris, France, M.D. (1981)
• University of Paris, France, Diploma in Tropical medicine, Public Health & Epidemiology (1982)Appearing: DAY 1 TUESDAY 21 SEPTEMBER – REGULATION & REIMBURSEMENT IN EUROPE 9.40am A decade of Herceptin and other targeted therapies: understanding the shift in the oncology market
- Mapping the scientific, clinical and commercial progress of Herceptin as a targeted cancer therapy.
- How the early success of Herceptin and other targeted therapies has shaped Big Pharma approaches to personalised medicine.
- Placing the current market for targeted cancer therapy in the context of Herceptin and other early blockbusters.
Jean-Jacques Garaud, Head of Pharma Research and Early Development,
Roche 12.40pm Panel discussion with Q&A: negotiating regulation, reimbursement and early TCT development
- Considering the fragmented nature of the disease vs the fragmented nature of the regulatory landscape.
- Incorporating the early-stage development of combined targeted cancer therapies into the existing regulatory model.
- Developing an industry-wide strategy for the improved data-streamlining, regulatory environment and reimbursement options of targeted cancer therapeutics.
Muriel Edith Rickman Chair in Breast Oncology, University of Manchester; Scientific Director Oncology, Karolinska University Hospital; Scientific Advisory Group on Oncology, Committee for Medicinal Products for Human Use,
EMEA Jean-Jacques Garaud, Head of Pharma Research and Early Development,
Roche Chief Medical Officer & Senior Vice President Global Clincial Sciences,
ImClone Systems, a wholly-owned subsidary of Eli Lilly & Co |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
